How would you treat an elderly, transplant-ineligible patient with recurrent DLBCL?
Would you treat differently for de novo disease vs disease arising from large cell transformation of an indolent NHL?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Rutgers Cancer Institute of New Jersey
Answered on
There is no single standard of care in the treatment of transplant-ineligible relapsed or refractory DLBCL in the second line. Many regimens would be considered relevant considerations here, including rituximab, gemcitabine, and oxaliplatin; bendamustine and rituximab; rituximab and dose-adjusted EP...
Join for free or sign in to see the full answer